Reading AHR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AHR free→Reading AHR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AHR free→NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, while risk is moderate and the sector backdrop is a headwind. Peer multiples imply a price about 145% below where it trades (it looks expensive on this basis); the read is rich. This valuation is conditional on the company's ability to maintain its performance amid sector challenges. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $46.81. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $47, AHR's earnings are too small for P/E to mean much; on sales it trades at 70× p/e (4.7× the 15× p/e peer median, and 1.0× even its own history). At a normal multiple the price implies ~146% near-term growth vs our ~23% forecast. That gap is an optionality premium a financial-multiple model can't price — our $19 fair value covers only the as-is business, low confidence. Analysts: $56–$60. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 146% near-term growth, well above our forecast of about 23%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Real Estate names rated strong grew net income 57% of the time over the next year (vs 54% for the rest of the cohort, n=1506).
Over the trailing year it converted 3.11x of net income into operating cash flow. Historically, Real Estate names rated robust grew net income 59% of the time over the next year (vs 50% for the rest of the cohort, n=1399).
Most sensitive to the broad stock market and real (inflation-adjusted) rates.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.18 → $0.14 (-25.0% / 30d). 0 raised, 2 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 92% of analysts rate Buy.
2 PT revisions / 30d. Avg target 12.7% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$118.
How much price usually moves either way.
On a bad day, this stock has moved -$269.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,363.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Keeping the $0.25 dividend is important. It helps build investor trust and manage funds.
Confirms:The official announcement says the dividend will stay at $0.25 per share.
Disproves:The announcement shows a cut in the dividend payout.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for AHR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. As previously announced, on May 22, 2026, we closed the public offering of 14,000,000 shares, or the Offering, of our common stock, $0.01 par value per share, or Common Stock. In connection with the Offering, BofA Securities, Inc., as underwriter, or in such capacity, the Underwriter, was granted an option for 30 days to purchase up to 2,100,000 additional shares of Common Stock. On May 26, 2026, in connection with the exercise in full of the Underwriter’s option to purchase add…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$56.00 – $60.00 (median $57.50) · 4 analysts · as of 2026-05-28
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care REITs.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
AHR American Healthcare REIT | Typical Show detailsSector percentile: 37 of 100 | expensive | moderate |
WELL Welltower | Typical Show detailsSector percentile: 58 of 100 | expensive | low |
VTR Ventas | Typical Show detailsSector percentile: 31 of 100 | expensive | moderate |
OHI Omega Healthcare Investors | Typical Show detailsSector percentile: 63 of 100 | expensive | moderate |
DOC Healthpeak Properties | Above typical Show detailsSector percentile: 72 of 100 | fair | moderate |
1 material management or governance event in the past 24 months, led by capital-allocation actions. Historically, Real Estate names rated neutral grew net income 57% of the time over the next year (vs 55% for the rest of the cohort, n=5004).
Not investment advice. As of 2026-06-12.
via XLRE
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue growth through strategic initiatives.
Commitment to maintaining a stable dividend of $0.25 per share.
Focus on improving net income through operational efficiencies.
Why it matters: Improving net income is crucial for long-term growth and stability.
Confirms:Net income for Q2 shows an increase of at least 5% year over year.
Disproves:Net income for Q2 declines or remains flat compared to the previous year.
Why it matters: Sector performance can impact AHR's growth. Changes in CPI may signal shifts.
Confirms one read:CPI report shows inflation rate below 2%, boosting sector outlook.
Confirms the other:CPI report shows inflation rate above 3%, creating headwinds for the sector.
Why it matters: Keeping net income above this level shows good cost control.
Confirms:Q2 net income is over $23.7M. This shows the company is running well.
Disproves:Q2 net income falls below $23.7M. This may show some problems.
Why it matters: Revenue growth is a top priority. Strong growth signals that the company is on track.
Confirms:Q2 revenue growth exceeds 7% year over year.
Disproves:Q2 revenue growth falls below 5% year over year.
Other Events. On May 22, 2026, we closed the public offering of 14,000,000 shares, or the Offering, of our common stock, $0.01 par value per share, or Common Stock. In connection with the Offering, we and American Healthcare REIT Holdings, LP, or our Operating Partnership, entered into an underwriting agreement on May 20, 2026, or the Underwriting Agreement, with BofA Securities, Inc., as underwriter, or in such capacity, the Underwriter, BofA Securities, Inc., as forward seller, or in such c…
Results of Operations and Financial Condition. On May 7, 2026, we issued an earnings release announcing our financial position as of March 31, 2026 and our results for the quarter then ended. A copy of the earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.